Who Paid My Doc
Troy Watson
Foot and Ankle Surgery Las Vegas, NV Medical Doctor
NPI 1780662817 CMS profile 35923
2800 E Desert Inn Rd Ste 100, Las Vegas, NV 89121
General payments
$1,249,245
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$88,574
Through program year 2025, Troy Watson of Las Vegas, NV is reported in the CMS Open Payments database as having received $1,249,245 across 625 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $88,574 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $222,909 | 57 | |
| 2024 | General | $187,166 | 54 | |
| 2023 | General | $163,264 | 61 | |
| 2022 | General | $182,104 | 80 | |
| 2021 | General | $211,507 | 149 | |
| 2020 | General | $98,826 | 79 | |
| 2019 | General | $183,470 | 145 |
Beside peers
- Troy Watson
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Troy Watson were reported at $222,909. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Troy Watson | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $183,470 | $1,327 | $279–$5,421 | $163 |
| 2020 | $98,826 | $795 | $121–$3,473 | $114 |
| 2021 | $211,507 | $1,289 | $201–$4,963 | $132 |
| 2022 | $182,104 | $1,539 | $270–$6,067 | $149 |
| 2023 | $163,264 | $1,117 | $257–$5,264 | $160 |
| 2024 | $187,166 | $1,064 | $235–$4,944 | $164 |
| 2025 | $222,909 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
121
Drug cost
$2,748
Branded share of claims
24%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Celecoxib | Generic | 52 | $2,031 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 29 | $507 | |
| Cephalexin | Generic | 40 | $210 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 133 billing codesPaid by Medicare
$153,491
Medicare patients
228
Services billed
2,525
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 74% | |
| Ischemic heart disease | 27% | |
| Diabetes | 24% | |
| Depression | 20% | |
| Osteoporosis | 19% | |
| Chronic kidney disease | 18% | |
| Atrial fibrillation | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 37 | 63 | $325 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 21 | 1,000 | $103 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
625 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Nevada
Roman Sibel
Foot and Ankle Surgery · Henderson, NV
Gregory Lundeen
Foot and Ankle Surgery · Reno, NV
Abdolreza Raissi
Foot and Ankle Surgery · Las Vegas, NV
Holman Chan
Foot and Ankle Surgery · Henderson, NV
Scott Whitlow
Foot and Ankle Surgery · Reno, NV
Paul Ryan
Foot and Ankle Surgery · Carson City, NV
Related records
Foot and Ankle Surgery in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.